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We read with great interest the study by Engvall and 
colleagues [1] in a recent issue of Arthritis Research & 
Th  erapy. Th  e study showed that anti-tumor necrosis 
factor-alpha (anti-TNF-α) inﬂ  iximab therapy is associa-
ted with an increase of body fat mass in early rheumatoid 
arthritis (RA) independently of changes in disease 
activity and levels of leptin and adiponectin.
With respect to this, we have prospectively followed a 
cohort of patients who had RA refractory to conventional 
disease-modifying antirheumatic drugs, including metho-
trexate, and who, owing to disease severity, underwent 
anti-TNF-α-inﬂ  iximab therapy. Among them, a subgroup 
of 33 consecutive RA patients who were on periodical 
treatment with inﬂ  iximab and who agreed to participate 
in the study was assessed to determine the short-term 
eﬀ   ect of this drug on insulin resistance, ghrelin, and 
adipokine proﬁ   le. Besides noting a dramatic improve-
ment of insulin resistance following inﬂ  iximab adminis-
tration [2], we observed that, upon administra  tion of this 
drug, serum ghrelin concentrations (in pico  grams per 
milliliter) increased signiﬁ  cantly (896.1 ± 314.8, median 
861.2, interquartile range (IQR) 700.5 to 879.9 before 
inﬂ  iximab at time 0 (baseline) and 976.3 ± 373.0, median 
905.8, IQR 752.6 to 1,152.8 after inﬂ  iximab infusion at 
120 minutes; P <0.001) and that increases in ghrelin 
concentrations were associated with reductions in 
P-selectin concentrations (r = −0.513; P = 0.002) [3]. 
How  ever, ghrelin concentrations were not related to the 
DAS28 (disease activity score using 28 joint counts), the 
mean erythrocyte sedimentation rate (ESR), and C-
reactive protein (CRP) from disease diagnosis or the ESR, 
platelet count, CRP, or cumulative prednisone dose at the 
time of the study [3]. Moreover, we observed a signiﬁ  cant 
correlation between leptin levels and body mass index 
[4].
Apart from stimulating growth hormone production, 
ghrelin regulates energy homeostasis through increasing 
food intake and decreasing fat utilization, leading to 
increased adiposity through growth hormone-indepen-
dent mechanisms [5]. Ghrelin is further associated with 
metabolic syndrome features, and ghrelin administration 
has beneﬁ  cial eﬀ  ects not only on cachexia in patients 
with heart failure and chronic obstructive pulmonary 
disease but also on insulin sensitivity in overweight 
patients and endothelial dysfunction in patients with 
metabolic syndrome [6]. Additionally, ghrelin has potent 
anti-inﬂ  ammatory  eﬀ   ects, including the inhibition of 
proinﬂ  ammatory cytokine production by T lymphocytes 
and monocytes within the immune system and human 
endothelial cells [7]. Besides noting the rapid decrease of 
P-selectin, a biomarker of endothelial dysfunction [8], we 
observed a rapid and signiﬁ  cant improvement of endo-
thelial function following inﬂ   iximab administration in 
these patients [9].
According to our observations, anti-TNF-α therapy 
increases serum levels of ghrelin. Since ghrelin has anti-
inﬂ  ammatory eﬀ  ects, increased levels presumably would 
be additive to the eﬃ   cacious actions of inﬂ  iximab [3].
Metabolic syndrome features are independently asso-
ciated with atherosclerosis in RA [10]. However, in our  © 2010 BioMed Central Ltd
Response to ‘Infl  iximab therapy increases body fat 
mass in early rheumatoid arthritis independently 
of changes in disease activity and levels of leptin 
and adiponectin: a randomized study over 
21 months’
Miguel A Gonzalez-Gay†1, Carlos Gonzalez-Juanatey2, Jose A Miranda-Filloy3, Javier Martin4, Maria T Garcia-Unzueta5 
and Javier Llorca*†6,7
See related research by Engvall et al., http://arthritis-research.com/content/12/5/R197
LETTER
†MAG-G and JL share senior authorship.
*Correspondence: llorcaj@unican.es
6Division of Epidemiology and Computational Biology, School of Medicine, 
University of Cantabria, Avda. Herrera Oria s/n. 39011-Santander, Spain
Full list of author information is available at the end of the article
Gonzalez-Gay et al. Arthritis Research & Therapy 2011, 13:404 
http://arthritis-research.com/content/13/2/404
© 2011 BioMed Central Ltdseries of patients with severe RA, in contrast to what was 
reported in non-RA subjects, metabolic syndrome 
features were not related to ghrelin concentrations [3]. It 
is possible that improvement of ghrelin metabolism 
through inhibition of cytokine production attenuates the 
cachexia in patients with RA. Additionally, in our series, 
we observed a signiﬁ  cant increase of body mass index 
when values obtained before the onset of inﬂ  iximab 
therapy were compared with those observed after 2 years 
of inﬂ  iximab therapy (unpublished observations).
Considering all of these observations, we feel that, in 
patients with severe RA, the TNF-α blockade may 
improve the impaired production of ghrelin, a hormone 
that is implicated in RA-associated cachexia. Th  is  eﬀ  ect 
may lead to an increase of body mass index in RA 
patients undergoing TNF-α antagonist therapy.
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